PL3291679T3 - Zmiana populacji drobnoustrojowych i modyfikowanie mikrobioty - Google Patents

Zmiana populacji drobnoustrojowych i modyfikowanie mikrobioty

Info

Publication number
PL3291679T3
PL3291679T3 PL16719873T PL16719873T PL3291679T3 PL 3291679 T3 PL3291679 T3 PL 3291679T3 PL 16719873 T PL16719873 T PL 16719873T PL 16719873 T PL16719873 T PL 16719873T PL 3291679 T3 PL3291679 T3 PL 3291679T3
Authority
PL
Poland
Prior art keywords
microbiot
modifying
change
microbial population
microbial
Prior art date
Application number
PL16719873T
Other languages
English (en)
Inventor
Jasper Clube
Morten Sommer
Christian GRØNDAHL
Eric VAN DER HELM
Ruben VAZQUEZ-URIBE
Original Assignee
Snipr Technologies Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57217569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3291679(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1507774.6A external-priority patent/GB201507774D0/en
Priority claimed from GBGB1507775.3A external-priority patent/GB201507775D0/en
Priority claimed from GBGB1507773.8A external-priority patent/GB201507773D0/en
Priority claimed from GBGB1507776.1A external-priority patent/GB201507776D0/en
Priority claimed from GBGB1508461.9A external-priority patent/GB201508461D0/en
Priority claimed from GBGB1509366.9A external-priority patent/GB201509366D0/en
Priority claimed from GBGB1510891.3A external-priority patent/GB201510891D0/en
Priority claimed from GBGB1518402.1A external-priority patent/GB201518402D0/en
Priority claimed from GB1600417.8A external-priority patent/GB2531454A/en
Priority claimed from GBGB1600418.6A external-priority patent/GB201600418D0/en
Application filed by Snipr Technologies Limited filed Critical Snipr Technologies Limited
Publication of PL3291679T3 publication Critical patent/PL3291679T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/20—Bacteria; Substances produced thereby or obtained therefrom
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/60—Isolated nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
PL16719873T 2015-05-06 2016-05-03 Zmiana populacji drobnoustrojowych i modyfikowanie mikrobioty PL3291679T3 (pl)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
GBGB1507775.3A GB201507775D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (3)
GBGB1507773.8A GB201507773D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (1)
GBGB1507776.1A GB201507776D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (4)
GBGB1507774.6A GB201507774D0 (en) 2015-05-06 2015-05-06 Products, uses & methods (2)
GBGB1508461.9A GB201508461D0 (en) 2015-05-17 2015-05-17 Products uses and methods (4.2)
GBGB1509366.9A GB201509366D0 (en) 2015-05-31 2015-05-31 Products, uses & methods (6)
GBGB1510891.3A GB201510891D0 (en) 2015-06-20 2015-06-20 Products, uses & methods (7)
GBGB1518402.1A GB201518402D0 (en) 2015-10-17 2015-10-17 Products, uses & methods (8)
GB1600417.8A GB2531454A (en) 2016-01-10 2016-01-10 Recombinogenic nucleic acid strands in situ
GBGB1600418.6A GB201600418D0 (en) 2016-01-10 2016-01-10 Products, uses & methods (1.2)
PCT/EP2016/059803 WO2016177682A1 (en) 2015-05-06 2016-05-03 Altering microbial populations & modifying microbiota
EP16719873.8A EP3291679B1 (en) 2015-05-06 2016-05-03 Altering microbial populations & modifying microbiota

Publications (1)

Publication Number Publication Date
PL3291679T3 true PL3291679T3 (pl) 2022-04-25

Family

ID=57217569

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16719873T PL3291679T3 (pl) 2015-05-06 2016-05-03 Zmiana populacji drobnoustrojowych i modyfikowanie mikrobioty

Country Status (17)

Country Link
US (30) US9701964B2 (pl)
EP (12) EP3907285A1 (pl)
JP (5) JP2018515138A (pl)
KR (4) KR20200091499A (pl)
CN (3) CN107667173A (pl)
AU (6) AU2016257306B2 (pl)
CA (1) CA2984975A1 (pl)
DE (1) DE112016002056T5 (pl)
DK (1) DK3291679T3 (pl)
ES (1) ES2905525T3 (pl)
IL (4) IL293646B2 (pl)
NZ (1) NZ738068A (pl)
PL (1) PL3291679T3 (pl)
RU (1) RU2017142352A (pl)
SG (1) SG11201708706YA (pl)
SI (1) SI3291679T1 (pl)
WO (1) WO2016177682A1 (pl)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548761B2 (en) 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
IL239317B (en) 2012-12-12 2022-07-01 Broad Inst Inc Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
US10660943B2 (en) 2013-02-07 2020-05-26 The Rockefeller University Sequence specific antimicrobials
US11135273B2 (en) 2013-02-07 2021-10-05 The Rockefeller University Sequence specific antimicrobials
EP3725885A1 (en) 2013-06-17 2020-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
JP6665088B2 (ja) 2013-06-17 2020-03-13 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための最適化されたＣＲＩＳＰＲ−Ｃａｓ二重ニッカーゼ系、方法および組成物
MX2015017312A (es) 2013-06-17 2017-04-10 Broad Inst Inc Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
WO2015066119A1 (en) 2013-10-30 2015-05-07 North Carolina State University Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
CN111206032B (zh) 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
BR112016013547A2 (pt) 2013-12-12 2017-10-03 Broad Inst Inc Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos
RU2016128077A (ru) 2013-12-12 2018-12-06 Те Брод Инститьют Инк. Доставка, применение и применения в терапии систем и композиций crispr-cas для лечения обусловленных hbv и вирусных заболеваний и нарушений
WO2015089473A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
WO2015089486A2 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
EP3129490A4 (en) 2014-04-08 2017-10-04 North Carolina State University Methods and compositions for rna-directed repression of transcription using crispr-associated genes
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10450584B2 (en) 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
EP3230451B1 (en) 2014-12-12 2021-04-07 The Broad Institute, Inc. Protected guide rnas (pgrnas)
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
KR20200091499A (ko) 2015-05-06 2020-07-30 스니프르 테크놀로지스 리미티드 미생물 개체군 변경 및 미생물군 변형
WO2016196361A1 (en) * 2015-05-29 2016-12-08 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
JP7051438B2 (ja) * 2015-06-15 2022-04-11 ノース カロライナ ステート ユニバーシティ 核酸およびｒｎａに基づく抗菌剤の効率的な送達のための方法および組成物
IL293323B2 (en) 2015-06-18 2024-01-01 Massachusetts Inst Technology Crispr enzyme mutations reducing off-target effects
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
WO2017058751A1 (en) 2015-09-28 2017-04-06 North Carolina State University Methods and compositions for sequence specific antimicrobials
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
WO2017112620A1 (en) 2015-12-22 2017-06-29 North Carolina State University Methods and compositions for delivery of crispr based antimicrobials
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3592381A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Cancer vaccine
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11267738B2 (en) * 2017-04-24 2022-03-08 Microbe Detectives Llc Method of using microbial DNA sequencing in recovering renewable resources from wastewater and other waste streams
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
US20230193241A1 (en) * 2017-06-25 2023-06-22 Snipr Technologies Limited Altering microbial populations & modifying microbiota
GB201710126D0 (en) * 2017-06-25 2017-08-09 Snipr Tech Ltd Vectors & Methods
CN111511394B (zh) * 2017-07-12 2024-02-06 布里格姆妇女医院 具有益生菌特性的活减毒霍乱疫苗
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
GB201712733D0 (en) 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
WO2019055582A1 (en) * 2017-09-12 2019-03-21 Ubabiologix Corp. COMPOSITIONS AND METHODS FOR SANITATION OF WASTE WATER
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
WO2019102381A1 (en) 2017-11-21 2019-05-31 Casebia Therapeutics Llp Materials and methods for treatment of autosomal dominant retinitis pigmentosa
CA3084954A1 (en) 2017-12-05 2019-06-13 BioPlx, Inc. Methods and compositions to prevent microbial infection
CN109899053B (zh) * 2017-12-08 2022-02-01 中国石油天然气股份有限公司 钻井井场的确定方法、装置及计算机可读存储介质
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
CN109971778B (zh) * 2017-12-27 2022-11-18 北京蓝晶微生物科技有限公司 一种在盐单胞菌中快速基因编辑的载体组合及其应用
CN108410880B (zh) * 2018-01-26 2021-10-22 昆明理工大学 一种丹波黑大豆柠檬酸转运蛋白基因及其应用
SG11202009504YA (en) 2018-03-25 2020-10-29 Snipr Biome Aps Treating & preventing microbial infections
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
AU2019262200A1 (en) * 2018-05-04 2020-12-17 Locus Biosciences, Inc. Methods and compositions for killing a target bacterium
CN108588050B (zh) * 2018-05-14 2021-06-25 北京艾克伦医疗科技有限公司 Dna聚合酶以及核酸检测方法和试剂盒
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
EP3817556A4 (en) * 2018-05-25 2022-03-30 Locus Biosciences, Inc. METHODS AND COMPOSITIONS FOR KILLING A TARGET BACTERIA
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
EP3821021A4 (en) * 2018-07-11 2021-09-15 Société de commercialisation des produits de la recherche appliquée SOCPRA Sciences Santé et Humaines s.e.c. BACTERIAL CONJUGATIVE SYSTEM AND THERAPEUTIC USES THEREOF
CN109136128B (zh) * 2018-08-23 2021-07-16 国家海洋局第一海洋研究所 一种副球菌及其筛选方法和在合成银纳米颗粒中的应用
US12144834B2 (en) 2018-09-13 2024-11-19 Xbiome Inc. Methods and compositions for treating gastrointestinal and inflammatory disorders
WO2020072250A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression
WO2020072253A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for screening for variant cells
US10711267B2 (en) 2018-10-01 2020-07-14 North Carolina State University Recombinant type I CRISPR-Cas system
US12264330B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
CN111119818B (zh) * 2018-10-30 2022-04-12 中国石油化工股份有限公司 一种油藏内源功能微生物定向调控的方法
EP3908298A4 (en) * 2019-01-11 2022-08-24 The Trustees of Columbia University in the City of New York Microbiome engineering through engineered mobile genetic elements
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
WO2020176624A1 (en) * 2019-02-26 2020-09-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Probiotics and probiotic compositions having modified carbohydrate metabolism
EP3935179A4 (en) * 2019-03-07 2022-11-23 The Trustees of Columbia University in the City of New York RNA-GUIDED DNA INTEGRATION USING TN7-LIKE TRANSPOSONS
EP3942043A2 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN110499353B (zh) * 2019-08-09 2023-11-07 佛山市第四人民医院(佛山市结核病防治所) 一种用于结核耐药诊断的微生物标志物及其应用
GB201913045D0 (en) * 2019-09-10 2019-10-23 Univ Oxford Innovation Ltd Biofilm transformation
CN110596364B (zh) * 2019-09-12 2020-06-23 江南大学 一种前列腺特异性抗原检测的比率电化学传感器的构建方法及其应用
EP4031155A4 (en) * 2019-09-18 2023-10-18 Ancilia, Inc. Compositions and methods for microbiome modulation
JP2022549519A (ja) * 2019-09-30 2022-11-25 シグマ－アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー 標的化ヌクレアーゼを用いたマイクロバイオータ組成の調節
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
JP2022554347A (ja) * 2019-11-06 2022-12-28 ローカス バイオサイエンシーズ，インク． Ｃｒｉｓｐｒ ｃａｓシステムを含むファージ組成物および溶原性モジュール
CA3162622A1 (en) * 2019-11-25 2021-06-03 Baylor College Of Medicine Selective expansion of gene-targeted cells
US20230046246A1 (en) * 2019-12-13 2023-02-16 The Regents Of The University Of California Reducing Antibiotic Resistance in Bacteria Using Pro-Active Genetics
DE102020101859A1 (de) * 2020-01-27 2021-07-29 Oxana Karpf Verfahren zur Reduktion der Population mindestens einer adipogenen Bakterienart umfassend Bakteriophagen sowie Bakteriophagen und deren Verwendung
CA3171941A1 (en) * 2020-03-16 2021-09-23 Joseph E. Peters Compositions and methods comprising improved guide rnas
WO2021195532A1 (en) * 2020-03-27 2021-09-30 The Trustees Of Columbia University In The City Of New York Genome engineering using crispr rna-guided integrases
JP7527830B2 (ja) * 2020-04-16 2024-08-05 旭化成株式会社 セルロース繊維乾燥体の製造方法、及び樹脂複合体の製造方法
JP7504650B2 (ja) * 2020-04-16 2024-06-24 旭化成株式会社 セルロース繊維乾燥体及びその製造方法、並びに樹脂複合体の製造方法
JP7488096B2 (ja) * 2020-04-16 2024-05-21 旭化成株式会社 セルロース繊維乾燥体及びその製造方法、並びに樹脂複合体の製造方法
BR112022022603A2 (pt) 2020-05-08 2023-01-17 Broad Inst Inc Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla
WO2021231689A1 (en) * 2020-05-14 2021-11-18 Chan Zuckerberg Biohub, Inc. Phage-mediated delivery of genes to gut microbiome
GB202007943D0 (en) 2020-05-27 2020-07-08 Snipr Biome Aps Products & methods
DE21179356T1 (de) * 2020-06-12 2022-02-17 Eligo Bioscience Spezifische entkolonisierung von antibiotikaresistenten bakterien für prophylaktische zwecke
EP4164390A4 (en) * 2020-06-16 2024-05-29 DSM IP Assets B.V. COMPOSITION FOR REDUCING THE RISK OF URINARY TRACT INFECTION AND VAGINAL INFECTION IN WOMEN
CN111849822A (zh) * 2020-07-28 2020-10-30 上海海洋大学 对抗菌素敏感的非o1/o139型霍乱弧菌菌株及应用
US12616602B2 (en) * 2020-08-06 2026-05-05 Hollister Incorporated Bacteria formulation and products including same
WO2022081428A1 (en) * 2020-10-16 2022-04-21 Nubiyota Llc Bacterial compositions and methods of use thereof for treatment of metabolic syndrome
CN113201531B (zh) * 2021-04-27 2023-06-27 隆平生物技术(海南)有限公司 转基因玉米事件lw2-1及其检测方法
US20240384279A1 (en) * 2021-08-01 2024-11-21 Snipr Biome Aps Microbiota engineering
US20250084398A1 (en) * 2021-08-02 2025-03-13 Trobix Bio Ltd Systems for modulating drug metabolism by cells, methods and compositions thereof
EP4479933A1 (en) 2022-02-15 2024-12-25 10x Genomics, Inc. Systems and methods for spatial analysis of analytes using fiducial alignment
CN114591879B (zh) * 2022-05-11 2022-12-06 中国农业大学 一种抑制幽门螺杆菌的发酵乳杆菌及其应用
PL4392550T3 (pl) 2022-06-29 2025-10-06 Snipr Biome Aps. Ukierunkowanie na komórki e. coli
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
EP4562144A1 (en) * 2022-07-25 2025-06-04 Trobix Bio Ltd Systems for modulating microbiome target cells, methods and compositions thereof
AU2023362887A1 (en) * 2022-10-17 2025-04-24 Locus Biosciences, Inc. Staphylococcus phage compositions and cocktails thereof
CN116042450B (zh) * 2022-11-03 2024-10-01 杭州秀川科技有限公司 一株高效降解苯胺类物质的陶厄氏菌及其应用
CN116058432B (zh) * 2023-03-02 2023-06-16 莱芜泰禾生化有限公司 一种柠檬酸菌丝渣微生物饲料添加剂及其制备方法和应用
CN116694535B (zh) * 2023-07-20 2024-08-23 四川大学 一种戊糖乳杆菌w19及其应用
GB202402011D0 (en) 2024-02-14 2024-03-27 Snipr Biome Aps A novel type of crispr/cas system
WO2025093778A1 (en) * 2023-11-05 2025-05-08 Human Biome Institute S.A. Functional compositions and methods of use thereof in eradication and/or decolonization of antibiotic-resistant bacteria and restoration of healthy microbiota
WO2025100495A1 (ja) * 2023-11-09 2025-05-15 株式会社bacterico 自己細菌の自己利用方法、自己利用システム、及び自己利用プログラム
WO2025132815A1 (en) 2023-12-20 2025-06-26 Novozymes A/S Novel cas nucleases and polynucleotides encoding the same

Family Cites Families (221)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US928A (en) * 1838-09-19 Eccentbic bbake eob abbesting the motion of bailboad-cabs
US3003323A (en) 1958-01-29 1961-10-10 Armco Steel Corp Composite pile connector
US4626504A (en) 1983-07-01 1986-12-02 Lubrizol Genetics, Inc. DNA transfer vector for gram-negative bacteria
SE8505027D0 (sv) 1985-10-24 1985-10-24 Kabigen Ab A lytic virulent phage, a hostcell containing same and a process for protein production
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DE4208785A1 (de) 1992-03-19 1993-09-23 Degussa Verfahren zum auffinden von insertionselementen (is-elemente) oder transposonen
JPH08506247A (ja) 1993-07-09 1996-07-09 アムジェン ボールダー インコーポレイテッド 組換えｃｔｌａ４ポリペプチドおよびその製造方法
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
US20030049841A1 (en) 1997-06-16 2003-03-13 Short Jay M. High throughput or capillary-based screening for a bioactivity or biomolecule
HRP20130077A2 (hr) 1998-12-23 2013-07-31 Pfizer Inc. Humana monoklonalna protutjela za ctla-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
AU2001229342A1 (en) 2000-01-11 2001-07-24 Intralytix, Inc. Method for produce sanitation using bacteriophages
WO2003060066A2 (en) 2001-11-07 2003-07-24 Musc Foundation For Research Development Nucleic acid delivery and expression
CA2396611A1 (en) 2002-07-31 2004-01-31 Plant Bioscience Limited Materials and methods for generating genetic disruptions in bacterial cells
KR101444717B1 (ko) 2003-07-02 2014-09-26 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
EP2292264A3 (en) 2003-07-24 2012-12-19 Innate Pharma Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
EP1677834B1 (en) 2003-10-06 2014-01-08 Gangagen, Inc. Defined dose therapeutic phage
AU2005324479A1 (en) 2004-04-07 2006-07-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reporter plasmid phage packaging system for detection of bacteria
WO2006003179A2 (en) 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
ES2374603T3 (es) 2005-01-06 2012-02-20 Novo Nordisk A/S Agentes de unión a kir y procedimientos de uso de los mismos.
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
NZ597299A (en) 2005-08-26 2013-03-28 Dupont Nutrition Biosci Aps Use of a cas gene in combination with CRISPR repeats for modulating resistance in a cell
CN101300272B (zh) 2005-10-14 2013-09-18 依奈特制药公司 用于治疗增生性病症的组合物和方法
EP2468765B1 (en) 2006-03-03 2015-04-22 ONO Pharmaceutical Co., Ltd. Tetramer of extracellular domain of PD-L1
US8445639B2 (en) 2006-05-15 2013-05-21 Avidbiotics Corporation Recombinant bacteriophage and methods for their use
WO2008076696A2 (en) * 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
US20100189723A1 (en) 2007-01-11 2010-07-29 Peter Andreas Nicolai Reumert Wagtmann Anti-kir antibodies, formulations, and uses thereof
PT2126130E (pt) 2007-03-02 2015-08-03 Dupont Nutrition Biosci Aps Culturas com resistência melhorada a fagos
US20110143997A1 (en) 2007-03-30 2011-06-16 Dow Agrosciences Llc Phage receptor binding proteins for antibacterial therapy and other novel uses
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010011961A2 (en) 2008-07-25 2010-01-28 University Of Georgia Research Foundation, Inc. Prokaryotic rnai-like system and methods of use
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
JP2012500652A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
US20100076057A1 (en) 2008-09-23 2010-03-25 Northwestern University TARGET DNA INTERFERENCE WITH crRNA
EP2367553B1 (en) 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
JP5344895B2 (ja) * 2008-12-10 2013-11-20 矢崎総業株式会社 充電監視装置
WO2010075424A2 (en) 2008-12-22 2010-07-01 The Regents Of University Of California Compositions and methods for downregulating prokaryotic genes
US8241498B2 (en) 2009-03-28 2012-08-14 Phage Biocontrol Research, Llc Process for remediating biofouling in water systems with virulent bacteriophage
JP2010285425A (ja) 2009-05-12 2010-12-24 Fujifilm Corp 腸内細菌叢構成比率調整剤
IN2012DN00863A (pl) 2009-07-31 2015-07-10 Medarex Inc
CA2772204A1 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
PL3053932T3 (pl) 2010-02-19 2021-03-08 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US8252576B2 (en) 2010-08-11 2012-08-28 Phage Biocontrol Research, Llc Use of prokaryote viruses to remediate bio-fouling
DK2630156T3 (en) * 2010-10-20 2018-12-17 Dupont Nutrition Biosci Aps CRISPR-CAS SEQUENCES OF LACTOCOCCUS
BR112013012138B1 (pt) 2010-11-22 2022-02-22 Innate Pharma Sa Uso de um composto que inibe um receptor inibidor de célula natural killer (nkcir)
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10835560B2 (en) 2013-12-20 2020-11-17 Joseph E. Kovarik Reducing the likelihood of skin cancer in an individual human being
US10245288B2 (en) 2011-02-04 2019-04-02 Joseph E. Kovarik Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US20180099001A1 (en) 2011-04-29 2018-04-12 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
US20140179726A1 (en) 2011-05-19 2014-06-26 Virginia Commonwealth University Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
ES2765874T3 (es) 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
WO2013025779A1 (en) 2011-08-15 2013-02-21 Amplimmune, Inc. Anti-b7-h4 antibodies and their uses
RU2470587C1 (ru) 2011-08-18 2012-12-27 Евгений Михайлович Рощин Способ определения расположения протетической верхней плоскости у пациентов с нарушениями целостности зубных рядов
US20130121968A1 (en) 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
HUE053444T2 (hu) 2011-10-28 2021-06-28 Regeneron Pharma Genetikailag módosított T-sejt receptoros egerek
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
AU2013256577B2 (en) 2012-04-30 2018-03-01 Sonomaceuticals, Llc Therapeutic use of Chardonnay seed products
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
LT3401400T (lt) 2012-05-25 2019-06-10 The Regents Of The University Of California Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui
WO2013187556A1 (en) 2012-06-14 2013-12-19 Scripps Korea Antibody Institute Novel antibody specific for clec14a and uses thereof
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US10025647B2 (en) 2012-06-30 2018-07-17 Intel Corporation Memory poisoning with hints
US20150290244A1 (en) 2012-07-13 2015-10-15 The Trustees Of The University Of Pennsylvania Use of cart19 to deplete normal b cells to induce tolerance
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
US9460205B2 (en) * 2012-07-20 2016-10-04 Google Inc. Crowdsourced video collaboration
JP2015527889A (ja) 2012-07-25 2015-09-24 ザ ブロード インスティテュート， インコーポレイテッド 誘導可能なｄｎａ結合タンパク質およびゲノム撹乱ツール、ならびにそれらの適用
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
DK2895012T3 (en) 2012-09-11 2018-01-22 Thylabisco Ab PREBIOTIC THYLAKOID COMPOSITION
EA201590522A1 (ru) 2012-09-13 2015-06-30 Саликс Фармасьютикалс, Инк. Способы введения рифаксимина для снижения веса и лечения ожирения
US11060148B2 (en) 2012-10-16 2021-07-13 Dana-Farber Cancer Institute, Inc. Diagnosing and treating colorectal cancer
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
CN114634950A (zh) 2012-12-12 2022-06-17 布罗德研究所有限公司 用于序列操纵的crispr-cas组分系统、方法以及组合物
EP3919505B1 (en) 2013-01-16 2023-08-30 Emory University Uses of cas9-nucleic acid complexes
US10660943B2 (en) 2013-02-07 2020-05-26 The Rockefeller University Sequence specific antimicrobials
US11135273B2 (en) * 2013-02-07 2021-10-05 The Rockefeller University Sequence specific antimicrobials
US9593339B1 (en) * 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
SG11201507378UA (en) 2013-03-14 2015-10-29 Caribou Biosciences Inc Compositions and methods of nucleic acid-targeting nucleic acids
EP2971148A4 (en) 2013-03-14 2016-08-17 Seres Therapeutics Inc METHODS OF DETECTING PATHOGENS AND ENRICHING FROM MATERIALS AND COMPOSITIONS
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
WO2014165707A2 (en) 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
EP2994530A4 (en) 2013-05-10 2016-11-16 Whitehead Biomedical Inst PROTEIN MODIFYING LIVING CELLS USING SORTASE
JP6665088B2 (ja) 2013-06-17 2020-03-13 ザ・ブロード・インスティテュート・インコーポレイテッド 配列操作のための最適化されたＣＲＩＳＰＲ−Ｃａｓ二重ニッカーゼ系、方法および組成物
ES2902386T1 (es) 2013-07-01 2022-03-28 Massachusetts Inst Technology Funcionalización de bacterias endógenas
DE102013012448A1 (de) 2013-07-26 2015-01-29 Kuka Laboratories Gmbh Verfahren und Vorrichtung zum Bremsen einer Roboterachsanordnung
JP5729429B2 (ja) * 2013-07-29 2015-06-03 トヨタ自動車株式会社 接合構造、及び接合構造の製造方法
RU2016107426A (ru) 2013-08-02 2017-09-07 Адуро Байотек Холдингс, Юроуп Б.В. Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета
US9944925B2 (en) 2013-08-02 2018-04-17 Enevolv, Inc. Processes and host cells for genome, pathway, and biomolecular engineering
US20150044772A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. Crispr/cas system-based novel fusion protein and its applications in genome editing
US10760065B2 (en) 2013-09-05 2020-09-01 Massachusetts Institute Of Technology Tuning microbial populations with programmable nucleases
US20150070747A1 (en) * 2013-09-09 2015-03-12 Qualcomm Mems Technologies, Inc. Display element reset using polarity reversal
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
ES2844174T3 (es) 2013-09-18 2021-07-21 Kymab Ltd Métodos, células y organismos
WO2015048577A2 (en) * 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
WO2015058018A1 (en) 2013-10-17 2015-04-23 National University Of Singapore Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US10767156B2 (en) 2013-10-24 2020-09-08 Yeda Research And Development Co., Ltd. Polynucleotides encoding BREX system polypeptides and methods of using same
US10752906B2 (en) 2013-11-05 2020-08-25 President And Fellows Of Harvard College Precise microbiota engineering at the cellular level
JP2016537418A (ja) 2013-11-05 2016-12-01 テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイアー エデュケーション 抗菌剤としてのポリカチオン両親媒性物質
CN106459995B (zh) 2013-11-07 2020-02-21 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US20150132263A1 (en) 2013-11-11 2015-05-14 Radiant Genomics, Inc. Compositions and methods for targeted gene disruption in prokaryotes
CA2930877A1 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
EP2876167A1 (en) 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
US20150157670A1 (en) * 2013-12-06 2015-06-11 K&K Ventures, LLC Non-caloric probiotic composition and method of preparation
WO2015088643A1 (en) 2013-12-11 2015-06-18 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
BR112016013547A2 (pt) * 2013-12-12 2017-10-03 Broad Inst Inc Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos
BR112016013213A2 (pt) 2013-12-12 2017-12-05 Massachusetts Inst Technology administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para visar distúrbios e doenças usando componentes de administração de partículas
JP6755801B2 (ja) 2014-01-29 2020-09-16 シンファジェン・リミテッド・ライアビリティ・カンパニーＳｙｎＰｈａＧｅｎ ＬＬＣ． 治療的な使用のための、核酸送達のための治療用ファージおよび方法
US10287590B2 (en) 2014-02-12 2019-05-14 Dna2.0, Inc. Methods for generating libraries with co-varying regions of polynuleotides for genome modification
ES3040431T3 (en) 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
JP2017512500A (ja) 2014-03-25 2017-05-25 ギンゴー バイオワークス， インコーポレイテッド 細胞工学のための方法および遺伝システム
WO2015148863A2 (en) * 2014-03-26 2015-10-01 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
EP3126503A1 (en) 2014-04-03 2017-02-08 Massachusetts Institute Of Technology Methods and compositions for the production of guide rna
EP3129490A4 (en) 2014-04-08 2017-10-04 North Carolina State University Methods and compositions for rna-directed repression of transcription using crispr-associated genes
CN106536739B (zh) * 2014-04-14 2021-08-03 内梅西斯生物有限公司 治疗剂
GB201406970D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Targeted mutations
GB201406968D0 (en) 2014-04-17 2014-06-04 Green Biologics Ltd Deletion mutants
US11584936B2 (en) 2014-06-12 2023-02-21 King Abdullah University Of Science And Technology Targeted viral-mediated plant genome editing using CRISPR /Cas9
BR112017000497B1 (pt) 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
US10450584B2 (en) 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
US11274317B2 (en) 2014-09-05 2022-03-15 Vilnius University Targeted RNA knockdown and knockout by type III-A Csm complexes
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
KR20170083534A (ko) 2014-09-19 2017-07-18 리제너론 파마슈티칼스 인코포레이티드 키메라 항원 수용체
AU2015334468B2 (en) 2014-10-23 2021-06-17 Institut Gustave Roussy Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
EP3224353B9 (en) 2014-11-26 2023-08-09 Technology Innovation Momentum Fund (Israel) Limited Partnership Targeted elimination of bacterial genes
WO2016183532A1 (en) 2015-05-13 2016-11-17 Synlogic, Inc. Bacteria engineered to treat a disease or disorder
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
US20160244784A1 (en) 2015-02-15 2016-08-25 Massachusetts Institute Of Technology Population-Hastened Assembly Genetic Engineering
MX385397B (es) 2015-03-02 2025-03-18 Synlogic Operating Co Inc Bacteria manejada genéticamente para producir butirato, interleucina-10 y/o interleucina-22 para tratar enfermedades que se benefician de inflamación intestinal reducida y/o barrera mucosa intestinal fortalecida.
EP3964234A1 (en) 2015-04-23 2022-03-09 Kaleido Biosciences, Inc. Glycan therapeutics and methods of treatment
KR20200091499A (ko) 2015-05-06 2020-07-30 스니프르 테크놀로지스 리미티드 미생물 개체군 변경 및 미생물군 변형
GB2531454A (en) 2016-01-10 2016-04-20 Snipr Technologies Ltd Recombinogenic nucleic acid strands in situ
US11883439B2 (en) 2015-05-13 2024-01-30 Synlogic Operating Company, Inc. Bacteria engineered to treat a disease or disorder
EP3294760B1 (en) 2015-05-13 2021-03-24 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
US20160347836A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
WO2016196361A1 (en) 2015-05-29 2016-12-08 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
MA43344A (fr) 2015-05-29 2018-04-11 Juno Therapeutics Inc Composition et procédés de régulation des interactions inhibitrices dans les cellules génétiquement modifiées
WO2016196605A1 (en) 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
JP7051438B2 (ja) 2015-06-15 2022-04-11 ノース カロライナ ステート ユニバーシティ 核酸およびｒｎａに基づく抗菌剤の効率的な送達のための方法および組成物
US10648020B2 (en) 2015-06-18 2020-05-12 The Broad Institute, Inc. CRISPR enzymes and systems
US11291693B2 (en) 2015-06-25 2022-04-05 Synlogic Operating Company, Inc. Bacteria engineered to treat metabolic diseases
EP3322797B1 (en) 2015-07-13 2023-11-29 Institut Pasteur Improving sequence-specific antimicrobials by blocking dna repair
US20170216370A1 (en) 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
GB201514510D0 (en) 2015-08-14 2015-09-30 Nemesis Bioscience Ltd Delivery vehicle
BR112018004532B1 (pt) 2015-09-10 2022-03-15 Université Catholique de Louvain Uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos
WO2017058751A1 (en) 2015-09-28 2017-04-06 North Carolina State University Methods and compositions for sequence specific antimicrobials
WO2017074566A1 (en) 2015-10-30 2017-05-04 Dean Falb Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
AU2016357554B2 (en) 2015-11-20 2019-04-04 Cj Bioscience, Inc. Compositions comprising bacterial strains
US11473104B2 (en) 2015-12-04 2022-10-18 Massachusetts Institute Of Technology Engineered phagemids
EP3394044A1 (en) 2015-12-17 2018-10-31 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
WO2017112620A1 (en) 2015-12-22 2017-06-29 North Carolina State University Methods and compositions for delivery of crispr based antimicrobials
WO2017118985A1 (en) 2016-01-06 2017-07-13 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
US20190010506A1 (en) 2016-01-11 2019-01-10 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
WO2017123418A1 (en) 2016-01-11 2017-07-20 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
US20190282628A1 (en) 2016-01-11 2019-09-19 Synlogic Inc. Recombinant bacteria engineered to treat diseases and disorders associated with amino acid metabolism and methods of use thereof
WO2017136795A1 (en) 2016-02-04 2017-08-10 Synlogic, Inc. Bacteria engineered to treat diseases associated with tryptophan metabolism
US20170247690A1 (en) 2016-02-25 2017-08-31 Agenovir Corporation Oncoviral treatment with nuclease and chemotherapeutic
WO2017152117A1 (en) 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
ES3041500T3 (en) 2016-03-10 2025-11-12 Cg Oncology Inc Methods of treating solid tumors by combination therapy
EP3448400A4 (en) 2016-04-25 2019-11-13 Yale University BACTERIOPHAGE COMPOSITIONS AND USES THEREOF
CN116850305A (zh) 2016-05-06 2023-10-10 朱诺治疗学股份有限公司 基因工程化细胞及其制备方法
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
CN116196425A (zh) 2016-09-27 2023-06-02 得克萨斯系统大学评议会 通过调节微生物组来增强免疫检查点阻断疗法的方法
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
WO2018081502A1 (en) 2016-10-28 2018-05-03 Massachusetts Intitute Of Technology Synthetic bacteriophages and bacteriophage compositions
AU2017376780B2 (en) 2016-12-15 2024-12-12 Novome Biotechnologies, Inc. Compositions and methods for modulating growth of a genetically modified gut bacterial cell
EP3559257A1 (en) 2016-12-22 2019-10-30 Institut Gustave Roussy (IGR) Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies and use of microbial modulators for improving the efficacy of an anti-pd1/pd-l1/pd-l2 ab-based treatment
US11149269B2 (en) 2017-05-15 2021-10-19 New York University Compositions and methods for non-antibiotic treating of bacterial infections by blocking or disrupting bacterial genes involved in virulence or viability
WO2018217351A1 (en) 2017-05-24 2018-11-29 Tets Viktor Veniaminovich Methods for treating and preventing diseases
WO2018218231A1 (en) 2017-05-25 2018-11-29 The Broad Institute, Inc. Lymphocyte antigen cd5like (cd5l) monomer, homodimer, and interleukin 12b (p40) heterodimer antagonists and methods of use thereof
US20200263186A1 (en) 2017-05-26 2020-08-20 North Carolina State University Altered guide rnas for modulating cas9 activity and methods of use
WO2018222969A1 (en) 2017-06-02 2018-12-06 Board Of Regents, The University Of Texas System Specific bacterial species and metabolite that improves immune checkpoint inhibitor therapy efficacy
EP3634473A4 (en) 2017-06-07 2021-03-24 The Rockefeller University ENHANCED CRISPR-TYPE GENE EDITING OR TARGET DESTRUCTION BY CO-EXPRESSION OF HETEROLOGICAL DNA REPAIR PROTEIN
US20230193241A1 (en) 2017-06-25 2023-06-22 Snipr Technologies Limited Altering microbial populations & modifying microbiota
GB201710126D0 (en) 2017-06-25 2017-08-09 Snipr Tech Ltd Vectors & Methods
GB201712733D0 (en) 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
US10303379B2 (en) 2017-09-25 2019-05-28 International Business Machines Corporation Efficient adaptive read-ahead in log structured storage
US20190160120A1 (en) 2017-11-29 2019-05-30 Snipr Biome Aps Dna, methods etc
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
AU2019262200A1 (en) 2018-05-04 2020-12-17 Locus Biosciences, Inc. Methods and compositions for killing a target bacterium
CA3102353A1 (en) 2018-06-19 2019-12-26 Glaxosmithkline Biologicals Sa Immunogenic composition
US12264330B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
WO2020072250A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression
US10711267B2 (en) 2018-10-01 2020-07-14 North Carolina State University Recombinant type I CRISPR-Cas system
WO2020072253A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for screening for variant cells
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
EP3894562A4 (en) 2018-12-11 2022-08-24 The University of Western Ontario CIS CONJUGATED PLASMID SYSTEM
KR102227515B1 (ko) 2018-12-18 2021-03-12 주식회사 포스코 제올라이트 및 그 제조방법
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
GB201912176D0 (en) 2019-08-23 2019-10-09 Snipr Biome Aps Plasmids
US20220403357A1 (en) 2019-11-12 2022-12-22 The Broad Institute, Inc. Small type ii cas proteins and methods of use thereof
WO2022003209A1 (en) 2020-07-03 2022-01-06 Eligo Bioscience Method of containment of nucleic acid vectors introduced in a microbiome population
GB202015255D0 (en) 2020-09-26 2020-11-11 Snipr Biome Aps Synthetic viruses
US20240384279A1 (en) 2021-08-01 2024-11-21 Snipr Biome Aps Microbiota engineering
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
PL4392550T3 (pl) 2022-06-29 2025-10-06 Snipr Biome Aps. Ukierunkowanie na komórki e. coli
GB202212688D0 (en) 2022-08-31 2022-10-12 Snipr Biome Aps A novel type of crispr/cas system
EP4677075A2 (en) 2023-03-06 2026-01-14 SNIPR Biome ApS Targeting cells in stressed growing conditions
GB202310227D0 (en) 2023-07-04 2023-08-16 Snipr Biome Aps Production & secretion of auxin-like molecules in bacteria

Also Published As

Publication number Publication date
US20220362280A1 (en) 2022-11-17
US20210386773A1 (en) 2021-12-16
RU2017142352A3 (pl) 2019-06-06
EP4233546A2 (en) 2023-08-30
US20220273696A1 (en) 2022-09-01
NZ738068A (en) 2019-07-26
RU2019130337A (ru) 2019-10-15
IL293646A (en) 2022-08-01
US11400110B2 (en) 2022-08-02
RU2017142352A (ru) 2019-06-06
KR102138209B1 (ko) 2020-07-28
AU2023202066A1 (en) 2023-05-11
IL255427B (en) 2021-10-31
EP3711488A1 (en) 2020-09-23
EP4570253A2 (en) 2025-06-18
US10582712B2 (en) 2020-03-10
US12226430B2 (en) 2025-02-18
US20180070594A1 (en) 2018-03-15
US20200337313A1 (en) 2020-10-29
EP3563684A1 (en) 2019-11-06
US11517582B2 (en) 2022-12-06
US11147830B2 (en) 2021-10-19
US20250161345A1 (en) 2025-05-22
US11547716B2 (en) 2023-01-10
US20220241318A1 (en) 2022-08-04
EP4005386A1 (en) 2022-06-01
US20220233575A1 (en) 2022-07-28
EP3291679A1 (en) 2018-03-14
US20200085066A1 (en) 2020-03-19
JP2026009952A (ja) 2026-01-21
US20190230936A1 (en) 2019-08-01
US20170246221A1 (en) 2017-08-31
AU2022202944B2 (en) 2023-01-05
US11844760B2 (en) 2023-12-19
IL310108B2 (en) 2025-05-01
US20160333348A1 (en) 2016-11-17
CN121891567A (zh) 2026-04-21
US11642363B2 (en) 2023-05-09
AU2019236694B2 (en) 2022-02-03
EP3291679B1 (en) 2021-12-15
US20210290654A1 (en) 2021-09-23
EP3729967A1 (en) 2020-10-28
JP2024038120A (ja) 2024-03-19
KR20250107283A (ko) 2025-07-11
EP4545082A2 (en) 2025-04-30
IL255427A0 (en) 2017-12-31
US20200068901A1 (en) 2020-03-05
US10506812B2 (en) 2019-12-17
US20240082289A1 (en) 2024-03-14
US20250228884A1 (en) 2025-07-17
US10624349B2 (en) 2020-04-21
HK1245016A1 (zh) 2018-08-24
RU2019130337A3 (pl) 2021-12-20
AU2022202944A1 (en) 2022-05-26
AU2024202021A1 (en) 2024-04-18
US20200077663A1 (en) 2020-03-12
US10524477B2 (en) 2020-01-07
US11612617B2 (en) 2023-03-28
US10463049B2 (en) 2019-11-05
US20180146681A1 (en) 2018-05-31
US20200128832A1 (en) 2020-04-30
US20180064114A1 (en) 2018-03-08
DK3291679T3 (da) 2022-01-17
US12514869B2 (en) 2026-01-06
US20200267992A1 (en) 2020-08-27
US20210283167A1 (en) 2021-09-16
AU2019236694A1 (en) 2019-10-17
EP4570253A3 (en) 2025-08-20
AU2016257306B2 (en) 2019-06-27
IL293646B1 (en) 2024-03-01
IL283877A (en) 2021-07-29
KR20230174291A (ko) 2023-12-27
US20200205416A1 (en) 2020-07-02
EP3461337A1 (en) 2019-04-03
US20210145006A1 (en) 2021-05-20
AU2016257306A1 (en) 2018-01-04
CN107667173A (zh) 2018-02-06
EP4545082A3 (en) 2025-07-02
US20180064115A1 (en) 2018-03-08
AU2024202021B2 (en) 2025-09-25
EP4169383A1 (en) 2023-04-26
US10561148B2 (en) 2020-02-18
US20180084786A1 (en) 2018-03-29
KR20200091499A (ko) 2020-07-30
IL293646B2 (en) 2024-07-01
SI3291679T1 (sl) 2022-04-29
CN114099712A (zh) 2022-03-01
JP2022106717A (ja) 2022-07-20
AU2023202066B2 (en) 2024-04-18
JP2020058369A (ja) 2020-04-16
IL310108A (en) 2024-03-01
US9701964B2 (en) 2017-07-11
US20250186479A1 (en) 2025-06-12
US20180084785A1 (en) 2018-03-29
AU2025283440A1 (en) 2026-01-22
IL283877B (en) 2022-07-01
US20190133135A1 (en) 2019-05-09
US12502401B2 (en) 2025-12-23
WO2016177682A1 (en) 2016-11-10
DE112016002056T5 (de) 2018-02-08
KR20180002776A (ko) 2018-01-08
ES2905525T3 (es) 2022-04-11
IL310108B1 (en) 2025-01-01
EP4233546A3 (en) 2023-09-27
SG11201708706YA (en) 2017-11-29
US20170196225A1 (en) 2017-07-13
EP3907285A1 (en) 2021-11-10
EP3903586A1 (en) 2021-11-03
US12514867B2 (en) 2026-01-06
CA2984975A1 (en) 2016-11-10
JP2018515138A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
IL293377A (en) Hsd17b13 variants and uses thereof
IL269534A (en) Chimeric molecules and uses thereof
IL256369A (en) Novel crispr enzymes and systems
EP3453019A4 (en) SMART LISTENLESEN
EP3547968A4 (en) PROSTHESIS OBTAINED BY TISSUE ENGINEERING
EP3626813A4 (en) INCUBATOR
PT3368534T (pt) Ditosilato de valbenazina e polimorfos do mesmo
DK3376859T3 (da) Mikroorganismer til fremstilling af insektferomoner og relaterede forbindelser
DK3291679T3 (da) Ændring af mikrobielle populationer og modificering af mikrobiota
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
PL3498292T3 (pl) Konstrukty białka uspa2 i ich zastosowania
LT3128005T (lt) Sirp-alfa varianto konstruktai, ir jų panaudojimas
EP3511407A4 (en) CHRISTENSENELLA INTESTINIHOMINIS AND APPLICATION THEREOF
PL3672948T3 (pl) Związki pirydynoamino-pirydonu i pirymidynoamino-pirydonu
DK3385377T3 (da) Bakteriemannanaser
DK3537878T3 (da) Algedræbende organismer
EP3356516A4 (en) CULTIVATION OF HUMAN NOROVIRES
EP3476932C0 (en) NEW MICROORGANISM BELONGING TO THE FAMILY OF SPORICHTHYACEAE AND ITS USE
EP3731928C0 (en) EJACULATION CONTROL
MA49905A (fr) Polyesteramines et polyesterquats
KR20180085008A (ko) 항-pcsk9 항체 및 그의 용도
DK3630961T3 (da) Genetisk konstrukt
EP3349748A4 (en) COMPOSITION AND METHOD THEREFOR
DK3672967T3 (da) Azaindolylpyridon- og diazaindolylpyridonforbindelser
EP3358010A4 (en) NOVEL ARTIFICIAL BIOLUMINESCENT ENZYME